Dr. Michael Deininger -Chronic Myeloid Leukemia - CML
|
Chief, Division of Hematology and Hematologic Malignancies
M.M. Wintrobe Professor of Medicine University of Utah Huntsman Cancer Institute ''Dr. Deininger's clinical interests center on leukemia, myeloproliferative neoplasms and hematopoietic stem cell transplantation. His research focuses on the biology of leukemia and development of molecularly targeted therapies for hematologic malignancies. The major focus of his lab is the molecular basis of resistance to tyrosine kinase inhibitors such as imatinib, a drug used to treat chronic myeloid leukemia and some other types of cancer. They are currently developing biomarker strategies to predict both response and resistance to tyrosine kinase inhibitor therapy.'' Extract of Huntsman Cancer Institute More info at University of Utah of medicine |
 |
Video Viewpoint on Community Oncology Clinical Debates: CML (Part1) VIDEO
July 9, 2012, IMERonline
Video Viewpoint on Community Oncology Clinical Debates: CML (Part2) VIDEO
July 9, 2012, IMERonline
A Video Viewpoint: Expert Discussions on CML Clinical Debates VIDEO
June 20, 2012, IMERonline
Stem Cell Transplant for Accelerated Phase CML VIDEO
March 9, 2012, Patient Power
Exploring Disease Risk and Treatment Options for CML VIDEO
February 24, 2012, Patient Power
Hematology: Curing CML with imatinib—a dream come true?
February 1, 2011, Nature Reviews Clinical Oncology
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR–ABL inhibitors as first-line therapy
February 2012, Leukemia
